Loading
A phase 2/3 trial of Lenalidomide, Daratumumab, Dexamethasone in multiple myeloma, run by AbbVie, now recruiting.
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant is a phase 2/3 interventional study registered as NCT07095452 by AbbVie, with 660 participants planned, started 2026-01-08 and due to reach its primary completion in 2042-01. Interventions recorded: Etentamig, Lenalidomide, Daratumumab, Dexamethasone, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Lenalidomide, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.